Detalhe da pesquisa
1.
Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.
Clin Infect Dis
; 75(1): e1028-e1036, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022711
2.
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Antimicrob Agents Chemother
; 65(5)2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33649113
3.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Sci Transl Med
; 14(628): eabl7430, 2022 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34941423
4.
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
medRxiv
; 2021 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159342
5.
Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.
medRxiv
; 2021 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34100024